| Similar Articles |
|---|
 |
The Motley Fool
March 25, 2009
Brian Orelli |
Wyeth: Now Approved to Kill More Bugs! Wyeth's antibiotic gets approved for another indication.   |
The Motley Fool
November 30, 2009
Brian Orelli |
The FDA Moves the Goalposts The FDA sends a complete response letter to Theravance about its antibiotic Vibativ, which it's trying to get approved for treating patients with nosocomial pneumonia. |
The Motley Fool
December 31, 2009
Brian Orelli |
The FDA (Still) Hates Antibiotic Makers Johnson & Johnson and Basilea are the agency's latest victims. |
The Motley Fool
May 30, 2008
Brian Orelli |
No Love for Antibiotics From the FDA Wyeth gets an approvable letter for its antibiotic Tygacil. |
The Motley Fool
February 16, 2010
Brian Orelli |
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward. |
The Motley Fool
August 21, 2008
Brian Orelli |
Johnson & Johnson Gets Rejected The FDA rejects Johnson & Johnson's bid to expand the label of its antibiotic. |
The Motley Fool
December 31, 2010
Brian Orelli |
2010 FDA Approvals and a Look Ahead Recent history can help us handicap FDA decisions. |
The Motley Fool
September 24, 2009
Brian Orelli |
Wyeth's Biting the Hand That Feeds It Wyeth decides to sue the Food and Drug Administration after it approved Orchid Chemicals & Pharmaceuticals' generic version of its antibiotic Zosyn. |
The Motley Fool
September 12, 2007
Brian Orelli |
Fitting Fission at Abraxis BioScience Abraxis BioScience will split itself into a biotech firm and a generic drug business. Both new companies stand to benefit, but will investors? |
The Motley Fool
February 23, 2010
Brian Orelli |
The One That Didn't Get Away After some encouragement, the FDA approves Gilead's Cayston. |
The Motley Fool
April 18, 2008
Brian Orelli |
Recalls Can't Beat Baxter In spite of charges for two recalls, Baxter posts a decent quarter. |
The Motley Fool
November 28, 2008
Brian Orelli |
The FDA's Killing Bug Killers Unfortunately for Johnson & Johnson and Swiss drugmaker Basilea Pharmaceutica, the FDA appears a little reluctant to take some of the data for the drugmakers' antibiotic ceftobiprole at face value. |
Chemistry World
May 6, 2014
Andy Extance |
WHO raises alarm on deadly bacteria The World Health Organization has warned antibiotic resistant bacteria could bring a nightmarish future, where seemingly trivial scrapes turn lethal, and currently routine operations become too risky to contemplate. |
Chemistry World
August 11, 2014
Phillip Broadwith |
Single shot antibiotic approved for skin infections Intravenous antibiotic Orbactiv oritavancin, from US firm The Medicines Company, has been approved by the US Food and Drug Administration. |
Pharmaceutical Executive
March 1, 2013
Jill Wechsler |
Another Round of FDA Legislation? Pressure for action on key enforcement and regulatory issues may prompt congressional action this year. |
The Motley Fool
August 24, 2009
Brian Orelli |
J&J Would Rather Not Say Drug delayed, reason unknown. Should shareholders be worried? It's hard to tell. |
The Motley Fool
September 24, 2008
Brian Orelli |
Hey, You! Stop! The FDA has ordered Baxter and Hospira to stop making their ophthalmic balanced salt solutions within 60 days. |
Chemistry World
May 12, 2011
Mike Brown |
Sugars recruited in fight against persistent infections Adding sugar to antibiotics can boost their effectiveness and prevent recurrent and chronic infections, according to researchers in the US. |
Chemistry World
April 27, 2011
Carol Stanier |
Drug cocktails greater than the sum of their parts Canadian scientists have shown that combining an antibiotic that is past its prime with other drugs can give it a new lease of life. |
BusinessWeek
October 29, 2007
Catherine Arnst |
Superbugs: Where Are the Wonder Drugs? Antibiotics are losing the battle against superbugs, and drugmakers are slow to replenish the arsenal. |
American Family Physician
January 15, 2004 |
Antibiotics: When They Can and Can't Help What are antibiotics?... Do antibiotics work against all infections?... What is "antibiotic resistance"?... Why should I worry about antibiotic resistance?... How do I know when I need antibiotics?... How should I take the antibiotics that my doctor prescribes?... etc. |
Chemistry World
December 11, 2014 |
Merck to buy antibiotics specialist Cubist Hours after the deal was announced, a US District Court invalidated several key patents for Cubist's top seller, Cubicin (daptomycin). |
The Motley Fool
December 31, 2007
Brian Lawler |
The Anatomy Of An Approved Drug An independent audit by the FDA provides a useful summary of the characteristics of drugs approved by the agency. |
American Family Physician
September 15, 2006 |
When Antibiotics Can Help A consumer's guide: What are antibiotics?... How do antibiotics work?... What is antibiotic resistance?... How can I prevent antibiotic resistance?... |
American Family Physician
October 1, 2004 |
Antibiotics: When They Can and Can't Help An overview on how antibiotic therapy comes into play in the treatment of the flu and colds. |
Chemistry World
February 6, 2013
Harriet Brewerton |
Diagnosing bacterial growth Antibiotics are used regularly for treating bacterial infections, but there is currently no quick and simple test to determine the most effective type or dose of antibiotic for a specific patient infection. |
American Family Physician
October 1, 2006 |
Antibiotics: When They Can and Can't Help What are antibiotics?... Do antibiotics always work?... What is bacterial resistance?... What can I do to help myself?... etc. |
The Motley Fool
March 31, 2010
Brian Orelli |
How Do You Put a Price on Pain? Price controls could wreck havoc on expensive therapies that control pain. |
American Family Physician
December 15, 2000 |
Antibiotics: When They Can and Can't Help Antibiotics are strong medicines that can stop some infections and save lives. When they aren't used the right way, antibiotics can cause more harm than good. You can protect yourself and your family by knowing when you should use antibiotics and when you should avoid them... |
The Motley Fool
November 11, 2004
Brian Gorman |
Hospira's Possibilities The medical products and services outfit is not flashy, but it may benefit from long-term trends. Their stock may be worth monitoring. |
Pharmaceutical Executive
October 1, 2008
Michael Bonney |
Specialty Sales Gets No Resistance The author, a Cubist Pharmaceuticals CEO. has given his company a successful start and is now predicting the future of drug resistance. |
American Family Physician
March 15, 2001 |
Avoiding Resistance to Antibiotics-- When Do I Need an Antibiotic? When bacteria are exposed to the same antibiotics, after a while the antibiotic can't fight the germs anymore... |
The Motley Fool
April 10, 2008
Brian Orelli |
The News for Baxter Just Got Worse These heparin-related deaths aren't associated with Baxter's product, but they still might spell trouble for the company. |
The Motley Fool
February 21, 2008
Brian Lawler |
A Bit of Irony From the FDA The agency has a mixed message on drug importation, as evidenced in the recent possible contamination of China-produced Heparin. |
The Motley Fool
October 10, 2005
Stephen D. Simpson |
The FDA: Boon, Bane, Whipping Boy Everyone wants the FDA to be faster, better, and cheaper, but that may not be a credible expectation. Investors would do well to keep an eye on the FDA because its policies and pressures ultimately filter down to our medicine cabinets, wallets, and portfolios. |
The Motley Fool
March 10, 2008
Brian Orelli |
Breakup Weighs Down APP It's going to take awhile for APP Pharmaceuticals to reward investors. |
The Motley Fool
February 12, 2009
Brian Orelli |
Stimulus Could Be Bitter Pill for Some Investors Health-care shareholders need to watch provisions of the stimulus bill closely. |
Nutrition Action Healthletter
May 2000 |
Magic Bullets Under Siege ...Antibiotics---drugs that kill bacteria---account for much of our success in the war against infectious illness. But the miracle drugs of medicine are in danger... |
Pharmaceutical Executive
March 1, 2012
Ron Cohen |
FDA's Necessary Dose of Reality There's no fast-acting salve, but there are several steps that can be taken to streamline many of the procedures at FDA. And it begins with leadership. |
AskMen.com
Harold Russell |
The Lowdown On Superbugs The overuse and misuse of antibiotics has led to the development of resistant strains of bacteria, commonly referred to as superbugs. |
The Motley Fool
January 26, 2011
Brian Orelli |
Health-Care Reform Lives: Here's Where to Invest State of the Union turned investment thesis regarding health insurance companies. |
Chemistry World
January 30, 2015
Rebecca Trager |
Billion dollar package unveiled to fight antibiotic resistance President Obama has made a huge investment in the fight against antibiotic resistant bacteria |
Chemistry World
March 28, 2014
Phillip Broadwith |
Baxter aims to divide and conquer US drugmaker Baxter International is spinning off its biopharmaceuticals business to create two independent companies. |
Chemistry World
May 19, 2015
Anthony King |
Roadmap to reward pharma for creating new antibiotics unveiled Pharma firms need better incentives to create novel antibiotics to head off an 'apocalyptic scenario' where commonplace infections become deadly once more. |
The Motley Fool
October 27, 2011
Alexander Crawford |
Medical Devices: Venture Capitalists Lobby to Change FDA Approval Process Do you think these firms stand to benefit from new regulations? |
Nursing Management
May 2011
Kirsten Drake |
SCIP core measures: Deep impact In August 2005, the SIP project grew to become a multiyear, national quality partnership of organizations called the Surgical Care Improvement Project, or SCIP, with the goal of decreasing surgical complication by 25% by 2010. |
The Motley Fool
April 20, 2006
Stephen D. Simpson |
Baxter Bags Better Margins This is a great business -- but only at the right price. Investors, this story has to be bought cheap. At today's prices, is it cheap enough? |
The Motley Fool
July 20, 2010
Brian Orelli |
Is J&J a Bad News Buy? Another quarter in 2010, another lowered earnings guidance for Johnson & Johnson. At least the year is half over for the health-care giant. |
Pharmaceutical Executive
June 1, 2012
Jill Wechsler |
Innovation and Collaboration A rash of "pro-innovative" approaches for testing and regulating medical products offer ways to speed more new products to market. |
The Motley Fool
February 29, 2008
Brian Orelli |
Bigger Recall, No Big Deal Baxter increases its recall of heparin, but investors shouldn't be that worried. |
